Table 3.

Standardized population pharmacokinetic parameter estimates (%CV is the coefficient of variation for the population parameter estimate, except for Vstd and CLstd, where between subject (BSV) and between occasion variability (BOV) were estimated; S.E. is the standard error of the structural parameter estimate, i.e. ‘stability' of the estimate).

Parameter	Estimate	%CV	S.E
Vstd.(l 70 kg−1)	69.9	BSV 18	3.6
		BOV 24
CLstd.(l h−1 70 kg−1)	13.0	BSV 41	0.8
		BOV 32
Felixir	1 fixed
tabs elixir.(h)	0.13	154	0.02
tlag elixir.(h)	0.39	31	0.02
Frectal/oral triglyceride base	0.67	30	0.07
tabs.triglyceride base (h)	1.34	90	0.61
tlag.triglyceride base (h)	0.14	31	0.10
Frectal/oral capsule	0.61	23	0.04
tabs.capsule (h)	0.65	63	0.07
tlag.capsule (h)	0.54	31	0.03

CLstd = population estimate for CL/F_oral (clearance after oral administration l h⁻¹ 70 kg⁻¹), Vstd = population estimate for V/F_oral (volume of distribution l 70 kg⁻¹), t_abs = absorption half-life after nasogastric (elixir), triglyceride base suppository and capsule suppository administration (h), t_lag = absorption lag time after nasogastric (elixir), triglyceride base suppository and capsule suppository administration (h), F_rectal/oral = relative bioavailability of the rectal compared with the oral formulation.